Document is current
Any future updates will be listed below
-
Authors
Massoud, Radwan https://orcid.org/0000-0001-9275-3840
Klyuchnikov, Evgeny
Heidenreich, Silke
Manjarres, Maroly Bohorquez
Rudolph, Ina
Krause, Rolf
Zeck, Gaby
Langebrake, Claudia
Dadkhah, Adrin https://orcid.org/0000-0002-3301-0059
Sabauri, Rusudan
Niederwieser, Christian https://orcid.org/0000-0002-0114-1011
Schäfersküpper, Mathias
Marquard, Franziska E.
Harfmann, Maraike
Oechsler, Sofia
Weise, Gunnar https://orcid.org/0009-0006-4546-7650
Rathje, Kristin
Gagelmann, Nico
Lueck, Catherina
Steiner, Normann https://orcid.org/0000-0001-9829-1309
Wolschke, Christine
Ayuk, Francis https://orcid.org/0000-0001-6297-1847
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
- License Information
-
More Information
Article History
Received: 25 March 2025
Revised: 7 October 2025
Accepted: 11 November 2025
First Online: 21 January 2026
Competing interests
: NK has received honoraria and consulting fees from Neovii, Novartis, MSD, Sanofi, Kite/Gilead, Kyverna, Medac, Jazz Pharmaceuticals, and Bristol Myers Squibb (BMS). All other authors declare no conflicts of interest.
